Lianbio Quick Ratio (LIAN) starting from the third quarter 2023 to third quarter 2022, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Lianbio  (NASDAQ: LIAN)

Lianbio's Quick Ratio

LIAN's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2023, Quick Ratio fell to 9.84 below Lianbio average.

Within Major Pharmaceutical Preparations industry 106 other companies have achieved higher Quick Ratio than Lianbio in third quarter 2023. While Quick Ratio total ranking in the third quarter 2023 has deteriorated compared to the prior quarter from 269 to 348.

Explain Quick Ratio?
How much Cash & cash equivalents LIAN´s has?
What are LIAN´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

LIAN Quick Ratio (Sep 30 2023)
Q3		 (Jun 30 2023)
Q2		 (Mar 31 2023)
Q1		 (Dec 31 2022)
Q4		 (Sep 30 2022)
Q3
Y / Y Current Liabilities Change 16.34 % -0.48 % 3.07 % 56.47 % -1.04 %
Y / Y Cash & cash equivalent Change -19.09 % -18.84 % -22.38 % -21.11 % 185.95 %
Quick Ratio MRQ 9.84 12.35 11.05 12.8 14.15
LIAN's Total Ranking # 348 # 269 # 323 # 288 # 232
Seq. Current Liabilities Change 18.41 % -16.52 % 9.78 % 7.21 % 1.29 %
Seq. Cash & cash equivalent Change -5.63 % -6.72 % -5.23 % -3 % -5.34 %



Quick Ratio third quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 107
Healthcare Sector # 180
Overall Market # 348


Quick Ratio Statistics
High Average Low
25.39 13.37 4.9
(Dec 31 2021)   (Sep 30 2021)




Financial Statements
Lianbio's Current Liabilities $ 26 Millions Visit LIAN's Balance sheet
Lianbio's Cash & cash equivalent $ 252 Millions Visit LIAN's Balance sheet
Source of LIAN's Sales Visit LIAN's Sales by Geography


Cumulative Lianbio's Quick Ratio

LIAN's Quick Ratio for the trailling 12 Months

LIAN Quick Ratio

 (Sep 30 2023)
12 Months		 (Jun 30 2023)
12 Months		 (Mar 31 2023)
12 Months		 (Dec 31 2022)
12 Months		 (Sep 30 2022)
12 Months
Y / Y Current Liabilities TTM Growth 15.22 % 10.63 % 37.57 % 116.84 % 204.57 %
Y / Y Cash & cash equivalent TTM Growth -20.45 % -1.92 % 10.23 % 75.8 % 283.47 %
Quick Ratio TTM 11.45 12.53 13.18 14.18 16.58
Total Ranking TTM # 3523 # 2554 # 2855 # 3072 # 2917
Seq. Current Liabilities TTM Growth 3.86 % -0.11 % 0.83 % 10.14 % -0.28 %
Seq. Cash & cash equivalent TTM Growth -5.1 % -5.04 % -6.29 % -5.8 % 17.02 %

Quick ratio ranking by company, industry and sector >> Back to LIAN Financial Strength Comparisons >> Go to Compare LIAN Quick Ratio to its Competitors

On the trailing twelve months basis Due to increase in Current Liabilities in the Q3 2023 to $25.63 millions, cumulative Quick Ratio decreased to 11.45 below the Lianbio average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 524 other companies have achieved higher Quick Ratio than Lianbio. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2023 from 2554 to 3523.

Explain Quick Ratio?
How much Cash & cash equivalents LIAN´s has?
What are LIAN´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 525
Healthcare Sector # 1035
Within the Market # 3523


trailing twelve months Quick Ratio Statistics
High Average Low
16.58 13.31 11.1
(Sep 30 2022)   (Mar 31 2022)




Companies with similar Quick Ratio in the quarter ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2023 MRQ Cash & cash equivalentSep 30 2023 MRQ Current Liabilities
Disc Medicine Inc   25.70 $ 370.541  Millions$ 14.416  Millions
Belite Bio Inc  24.27 $ 88.157  Millions$ 3.633  Millions
Janux Therapeutics Inc   24.17 $ 349.712  Millions$ 14.471  Millions
Bright Minds Biosciences Inc   24.16 $ 5.197  Millions$ 0.215  Millions
Design Therapeutics Inc   23.48 $ 290.940  Millions$ 12.390  Millions
Lixte Biotechnology Holdings Inc   23.08 $ 5.106  Millions$ 0.221  Millions
Anixa Biosciences Inc   23.06 $ 46.773  Millions$ 2.028  Millions
Diamedica Therapeutics Inc   22.23 $ 46.465  Millions$ 2.090  Millions
Terns Pharmaceuticals Inc   22.06 $ 266.600  Millions$ 12.087  Millions
Cyteir Therapeutics Inc   21.65 $ 129.242  Millions$ 5.969  Millions
Ars Pharmaceuticals Inc   21.64 $ 241.902  Millions$ 11.180  Millions
Lantern Pharma Inc   21.54 $ 44.926  Millions$ 2.085  Millions
Xenon Pharmaceuticals Inc   21.28 $ 526.674  Millions$ 24.744  Millions
Tyra Biosciences Inc   21.25 $ 215.652  Millions$ 10.147  Millions
Astria Therapeutics Inc   21.23 $ 188.806  Millions$ 8.894  Millions
Sagimet Biosciences inc   20.59 $ 101.842  Millions$ 4.946  Millions
Eledon Pharmaceuticals Inc   20.56 $ 59.609  Millions$ 2.899  Millions
Acelyrin Inc   20.41 $ 381.738  Millions$ 18.702  Millions
Akero Therapeutics Inc   19.50 $ 554.732  Millions$ 28.447  Millions
Pliant Therapeutics Inc   19.11 $ 523.612  Millions$ 27.395  Millions
Eqrx Inc   19.03 $ 1,212.933  Millions$ 63.726  Millions
Pmv Pharmaceuticals Inc   18.84 $ 201.918  Millions$ 10.716  Millions
Ideaya Biosciences Inc   18.83 $ 468.751  Millions$ 24.893  Millions
Savara Inc   18.77 $ 168.251  Millions$ 8.963  Millions
Medicinova Inc   18.38 $ 51.507  Millions$ 2.802  Millions
Immuneering Corporation  18.28 $ 97.243  Millions$ 5.321  Millions
Fulcrum Therapeutics Inc   18.27 $ 257.091  Millions$ 14.075  Millions
Stoke Therapeutics Inc   18.18 $ 214.718  Millions$ 11.811  Millions
Edgewise Therapeutics inc   17.73 $ 289.697  Millions$ 16.338  Millions
Kura Oncology Inc   17.51 $ 452.593  Millions$ 25.843  Millions

Date modified: 2026-09-08T15:11:07+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.